There is also a phase I/II clinical trial that examines KRAS mutant pancreatic cancer and combines three treatments: cobimetinib, HCQ, and atezolizumab, a PD-L1 antibody. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.